Advanced Filters
noise

Pain Clinical Trials

A listing of Pain medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,170 clinical trials
S Shangqian Wang, M.D.,PhD.

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.

40 - 80 years of age Male Phase 3
J Jing-Ren Tseng, MD

68Ga-PSMA PET/CT for Ra223 Assessment

Primary objective: i.The primary objective is to compare the diagnostic positivity in progression of 68Ga-PSMA PET and Bone scan. Secondary objectives: i.The correlation between PET osseous tumor burden index and Alk-P level ii.The correlation between PET osseous tumor burden index and PSA level

40 - 85 years of age Male Phase N/A
K Khurshid A. Guru

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy

This trial investigates brain and pelvic floor muscle activity in patients undergoing robot-assisted radical prostatectomy. This trial may help identify the brain waves that are associated with muscles involved in giving patients control over the bladder.

18 years of age Male Phase N/A
A Adriana Coletta, PHD, MS, RD

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and …

18 years of age Male Phase 3
S Sazan Rasul, PhD

PSMA-RLT in Biochemically Recurrent PCa

Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with …

18 - 80 years of age Male Phase 2
G Guochang Wang, MD

68Ga-AAZTA-093 PET/CT: First-in-human Study

68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.

18 - 90 years of age Male Phase N/A
S Site Public Contact

Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand …

18 years of age Male Phase N/A
J Jeremie Calais

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

In advanced metastatic castration resistant prostate cancer (mCRPC) progressing after chemotherapy and androgen receptor (AR)-targeted therapy 177Lu-PSMA-617 is an effective treatment. 177Lu-PSMA-617 RLT is administered with a fixed schedule: 6 treatment cycles, administered every 6 weeks. However, the optimum number of cycles of 177Lu-PSMA in patients who show good response …

18 years of age Male Phase 2
X Xiaojian Qin, MD.

Combination of TURP and Standard Systemic Therapy for MPCa

This is a Phase II, open-label, prospective, single-arm clinical study designed to evaluate the efficacy and safety of combining transurethral resection of the prostate (TURP) with standard systemic therapy in patients with metastatic prostate cancer (mPCa). All participants will undergo TURP to relieve urinary obstruction and reduce tumor burden, followed …

18 - 80 years of age Male Phase 2
D Dr.Vedang Murthy

Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial

Aim of the study to improve the treatment of high-risk non-metastatic prostate cancer by comparing reduced duration of hormone therapy to the standard duration of two years, when combined with curative intent standard of care radiotherapy to prostate and pelvic nodes. The reduced duration will be intensified with addition of …

19 - 99 years of age Male Phase 2

Simplify language using AI